

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
Commony	appeal)
Company	General
Janssen (guselkumab)	All Wales Therapeutics and Toxicology
Detient/serer groups	Centre
Patient/carer groups	Allied Health Professionals Federation
Bladder and Bowel Community	Board of Community Health Councils in
Bowel Cancer UK	Wales
Colostomy UK	British National Formulary
Crohn's and Colitis UK	Care Quality Commission
GUTS UK	Department of Health, Social Services
IA: Ileostomy and Internal Pouch	and Public Safety for Northern Ireland
Association	Healthcare Improvement Scotland
South Asian Health Foundation	Medicines and Healthcare products
Specialised Healthcare Alliance	Regulatory Agency
	National Association of Primary Care
Healthcare professional groups	 National Pharmacy Association
Association of Coloproctology of Great	NHS Confederation
Britain and Ireland	Scottish Medicines Consortium
Association of Surgeons of Great	Welsh Government
Britain and Ireland	Welsh Health Specialised Services
British Geriatrics Society	Committee
British Society of Gastroenterology	
Primary Care Society for	Possible comparator companies
Gastroenterology	AbbVie (adalimumab, risankizumab,
Royal College of Anaesthetists	upadacitinib)
Royal College of General Practitioners	Amgen (adalimumab)
Royal College of Nursing	Biogen - Biosimilars (adalimumab,
Royal College of Pathologists	infliximab)
Royal College of Physicians	Celltrion Healthcare UK (adalimumab,
Royal College of Surgeons of England	infliximab)
Royal Pharmaceutical Society	Eli Lilly (mirikizumab)
Royal Society of Medicine	Fresenius Kabi (adalimumab)
UK Clinical Pharmacy Association	Janssen (ustekinumab)
	Merck Sharp & Dohme (infliximab)
<u>Others</u>	Pfizer (infliximab)
Department of Health and Social Care	Sandoz (adalimumab, infliximab)
NHS England	Takeda UK (vedolizumab)

Provisional stakeholder list for the evaluation of guselkumab for previously treated moderately to severely active Crohn's disease ID6238



Consultees	Commentators (no right to submit or appeal)
	Relevant research groups
	 Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Genomics England MRC Clinical Trials Unit National Institute for Health Research
	Associated Public Health groups
	Public Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of guselkumab for previously treated moderately to severely active Crohn's disease ID6238

Issue date: May 2024